Search

Displaying all 4 results
DrugBest match

Sipuleucel-T

go.drugbank.com/drugs/DB06688
ApprovedInvestigational

Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared...

  1. Indication

    Minimally symptomatic, metastatic hormone-refractory Prostate cancer

    go.drugbank.com/conditions/DBCOND0023930
    Drugs: Sipuleucel-T
  2. Indication

    Asymptomatic, metastatic hormone-refractory Prostate cancer

    go.drugbank.com/conditions/DBCOND0023929
    Drugs: Sipuleucel-T
  3. Drug

    Radium Ra-223

    go.drugbank.com/drugs/DB12813
    Investigational

    Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).